Breaking News
Get 45% Off 0
👀 Ones to Watch: These bargain stocks won't stay cheap long
See Undervalued Stocks

Geoff Considine, Ph.D

  • Analysis & Comment

Geoff Considine, Ph.D's Comment & Analysis
A complete archive of Geoff Considine, Ph.D's articles, including current analysis & comment - Page 5

Nike Stock May Jump In First Half Of 2022
By Geoff Considine, Ph.D - Jan 19, 2022
Nike has had a volatile year and the shares are down 11.8% YTD The valuation is high Wall Street consensus is bullish, with about 25% expected 12-month gain The market-implied outlook for NKE is...
Union Pacific Corporation (and railroads, in general) have been strong performers over the past 15 years UNP is up 11.8% in the past 3 months The volume of rail transport for 2021 was significantly...
QCOM shares leapt after a big earnings beat at the start of November The shares have lagged the semi industry substantially over the past 12 months The company is poised for substantial growth in auto...
VIAC is a hybrid of traditional media with streaming services The market struggles with how to value this company The Wall Street analyst consensus is that the shares will rebound in the next year The...
Costco is an incredibly successful and well-run company Shareholders have enjoyed very high returns as the firm builds out e-commerce offerings The company is valued more like a tech firm than a...
Lennar is one of the US’s largest home builders The company is trading at a modest P/E of 7 The Q4 earnings, reported Dec. 15, slightly missed analyst expectations The Wall Street analyst...
IBM shares have been in decline over the past 5 years The current dividend yield is 5.2% The Wall Street consensus view continues to be bullish The market-implied outlook (calculated from options...
Edison International recently raised its dividend and currently yields 4.2% The shares have rallied over the past 3 months The potential liabilities from wildfires are large and hard to estimate The...
Gilead Sciences has near-term upside potential due to the widespread use of Veklury (remdesivir) to treat hospitalized COVID-19 patients The shares are cheap, but the 3-5 year outlook for growth is...
DocuSign (DOCU) is a leading provider of e-signature and related solutions The shares cratered in mid-November on weaker management guidance for Q4 The Wall Street consensus outlook is bullish, with...